HRP20050788A2 - Use of isoquinoline derivatives for treating cancer and map kinase related diseases - Google Patents

Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Info

Publication number
HRP20050788A2
HRP20050788A2 HR20050788A HRP20050788A HRP20050788A2 HR P20050788 A2 HRP20050788 A2 HR P20050788A2 HR 20050788 A HR20050788 A HR 20050788A HR P20050788 A HRP20050788 A HR P20050788A HR P20050788 A2 HRP20050788 A2 HR P20050788A2
Authority
HR
Croatia
Prior art keywords
map kinase
treating cancer
related diseases
isoquinoline derivatives
kinase related
Prior art date
Application number
HR20050788A
Other languages
English (en)
Croatian (hr)
Inventor
Bryant Batt David
Bold Guido
Kim Sunkyu
Michael Ramsey Timothy
Lloyd Sabio Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20050788A2 publication Critical patent/HRP20050788A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20050788A 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases HRP20050788A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
PCT/EP2004/002460 WO2004080464A1 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Publications (1)

Publication Number Publication Date
HRP20050788A2 true HRP20050788A2 (en) 2006-12-31

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050788A HRP20050788A2 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Country Status (22)

Country Link
EP (1) EP1603566B1 (https=)
JP (1) JP2006519807A (https=)
KR (1) KR20050108383A (https=)
CN (1) CN1758910A (https=)
AT (1) ATE421324T1 (https=)
AU (1) AU2004218914A1 (https=)
BR (1) BRPI0408257A (https=)
CA (1) CA2518530A1 (https=)
DE (1) DE602004019193D1 (https=)
ES (1) ES2318276T3 (https=)
HR (1) HRP20050788A2 (https=)
IS (1) IS8064A (https=)
MA (1) MA27724A1 (https=)
MX (1) MXPA05009687A (https=)
NO (1) NO20054647L (https=)
PL (1) PL1603566T3 (https=)
PT (1) PT1603566E (https=)
RU (1) RU2325159C2 (https=)
TN (1) TNSN05223A1 (https=)
TW (1) TW200501955A (https=)
WO (1) WO2004080464A1 (https=)
ZA (1) ZA200506571B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
JP2008517064A (ja) 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
JP5049970B2 (ja) * 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2639416C (en) * 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
US9056855B2 (en) * 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GT200000158A (es) * 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
DE60239097D1 (de) * 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
JP2006519807A (ja) 2006-08-31
CN1758910A (zh) 2006-04-12
NO20054647D0 (no) 2005-10-10
MA27724A1 (fr) 2006-01-02
PT1603566E (pt) 2009-04-27
MXPA05009687A (es) 2005-10-20
WO2004080464A1 (en) 2004-09-23
EP1603566B1 (en) 2009-01-21
AU2004218914A1 (en) 2004-09-23
TNSN05223A1 (en) 2007-06-11
DE602004019193D1 (de) 2009-03-12
ATE421324T1 (de) 2009-02-15
RU2325159C2 (ru) 2008-05-27
IS8064A (is) 2005-10-10
CA2518530A1 (en) 2004-09-23
PL1603566T3 (pl) 2009-07-31
TW200501955A (en) 2005-01-16
ZA200506571B (en) 2006-07-26
ES2318276T3 (es) 2009-05-01
NO20054647L (no) 2005-12-09
BRPI0408257A (pt) 2006-03-07
RU2005131168A (ru) 2006-05-27
EP1603566A1 (en) 2005-12-14
KR20050108383A (ko) 2005-11-16

Similar Documents

Publication Publication Date Title
HRP20050788A2 (en) Use of isoquinoline derivatives for treating cancer and map kinase related diseases
TNSN06093A1 (en) 1,4- disubstituted isoquinoline derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
UA96565C2 (ru) Пиридильные ингибиторы хеджхоговской передачи сигнала
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EA200801037A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
HRP20050041B1 (hr) UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
NO20060230L (no) Nye aminobenzofenonforbindelser
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
EA201990311A1 (ru) АНТИМЕТАСТАТИЧЕСКИЕ 2H-СЕЛЕНОФЕН[3,2-h]ХРОМЕНЫ, СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
ATE523199T1 (de) Pyridazinverbindungen und verfahren
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
NO20055650D0 (no) Ruteinum (II)-komplekser for behandling av tumorer
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE345795T1 (de) 1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivate und verwandte verbindungen als faktor xa inhibitoren zur behandlung von akuten gefässerkrankungen
DE502004008294D1 (de) Neue makrocyclen zur behandlung von krebserkrankungen
MA33958B1 (fr) Derives de pyrazine et leur utilisation dans le traitement de troubles neurologiques

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080310

Year of fee payment: 5

OBST Application withdrawn